Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models
Patients with ovarium cancer frequently develop resistance to platinum chemotherapy and PARP inhibitors (PARPi). Here, the authors show that the combination of PARP and ATR inhibitors increases the therapeutic response in PARPi and platinum resistant ovarium cancer PDX models.
Guardado en:
Autores principales: | Hyoung Kim, Haineng Xu, Erin George, Dorothy Hallberg, Sushil Kumar, Veena Jagannathan, Sergey Medvedev, Yasuto Kinose, Kyle Devins, Priyanka Verma, Kevin Ly, Yifan Wang, Roger A. Greenberg, Lauren Schwartz, Neil Johnson, Robert B. Scharpf, Gordon B. Mills, Rugang Zhang, Victor E. Velculescu, Eric J. Brown, Fiona Simpkins |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2020
|
Materias: | |
Acceso en línea: | https://doaj.org/article/cc35bbdbfeb9477db7745da1954cd683 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Real-time monitoring of PARP1-dependent PARylation by ATR-FTIR spectroscopy
por: Annika Krüger, et al.
Publicado: (2020) -
Myc targeted CDK18 promotes ATR and homologous recombination to mediate PARP inhibitor resistance in glioblastoma
por: Jian-Fang Ning, et al.
Publicado: (2019) -
Differential regulation of breast cancer bone metastasis by PARP1 and PARP2
por: Hao Zuo, et al.
Publicado: (2020) -
Serine-linked PARP1 auto-modification controls PARP inhibitor response
por: Evgeniia Prokhorova, et al.
Publicado: (2021) -
Dual function of HPF1 in the modulation of PARP1 and PARP2 activities
por: Tatyana A. Kurgina, et al.
Publicado: (2021)